Disease-modifying treatments (DMTs), which are the foundation of multiple sclerosis (MS) care, reduce clinical exacerbations (relapses) and slow disease progression; however, improving quality of life ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a ...

Please provide your email address to receive an email when new articles are posted on . In this exclusive video, William Sandborn, MD, from the University of California, San Diego, discusses research ...

Starting treatment for relapsing-remitting multiple sclerosis (MS) with high-efficacy therapy (HET) is associated with lower long-term disability compared with a step-wise increase to reach more ...

The ALLIANCE phase 2 trial demonstrated proof-of-concept after only 6 months of maintenance treatment in a broad patient population comprising both children and adults. Clear dose-dependent and ...

Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the ...

“We are very enthusiastic about the therapeutic potential of lenabasum in systemic sclerosis and dermatomyositis. In these ongoing open-label extension studies, lenabasum continues to have an ...

The presentation will feature an analysis of multiple efficacy endpoints, including Hammersmith scales and Revised Upper Limb Module (RULM) function, from the 12-month TOPAZ Phase 2 trial evaluating ...

The poster will present multiple efficacy endpoints, including Hammersmith scales and Revised Upper Limb Module (RULM) function, from the 12- month TOPAZ Phase 2 trial evaluating apitegromab in ...